Target intelligence / Profile preview

Transcription factor 4 (TCF4) CTG18.1 expanded CUG-repeat RNA (TCF4 CUG-repeat RNA)

Target
TCF4 CUG-repeat RNA
Molecular classification
RNA, Non-coding RNA, Toxic RNA, Microsatellite expansion RNA
01

Overview

The expanded TCF4 CTG18.1 CUG-repeat RNA is a pathogenic transcript resulting from a trinucleotide repeat expansion within the TCF4 gene, specifically at the intronic CTG18.1 locus (Wieben et al., 2012, PLoS ONE). This expansion, typically exceeding 40-50 repeats, is the most significant genetic risk factor for Fuchs' endothelial corneal dystrophy (FECD), a leading cause of corneal transplant surgery (Vithana et al., 2013, JAMA Ophthalmology). The resulting CUG-repeat RNA molecules accumulate in the nuclei of corneal endothelial cells, forming toxic RNA foci that are a hallmark of the disease (Zarouchlioti et al., 2018, American Journal of Human Genetics). These foci sequester essential RNA-binding proteins, most notably Muscleblind-like 1 (MBNL1), leading to widespread alternative splicing defects and subsequent cellular dysfunction (Mootha et al., 2015, Investigative Ophthalmology & Visual Science). Therapeutic interventions currently under investigation aim to target this toxic RNA using antisense oligonucleotides (ASOs) or small molecules to either induce its degradation or block its interaction with sequestered proteins (Hu et al., 2018, Molecular Therapy). Successfully reducing the burden of these RNA foci is expected to restore normal splicing patterns and preserve the function and density of corneal endothelial cells.

Other names
TCF4 CTG18.1 expansionExpanded CUG RNA in TCF4FECD-associated TCF4 RNACTG18.1 trinucleotide repeat RNA
02

Mechanism of action

Degradation of toxic expanded RNA via RNase H-mediated cleavage or steric hindrance to prevent the sequestration of RNA-binding proteins like MBNL1.

03

Biological functions

RNA processingSplicing regulation (disrupted)Protein sequestrationCellular homeostasis maintenance
04

Disease associations

Fuchs' endothelial corneal dystrophy (FECD)
05

Safety considerations

Off-target knockdown of wild-type TCF4 mRNAEfficient delivery to corneal endothelial cellsInnate immune activation by oligonucleotide therapiesLong-term stability of RNA-targeting effects
06

Interacting drugs

Antisense oligonucleotides (ASOs)

4 more in the full profile.

07

Biomarkers

Nuclear RNA foci in corneal endothelial cellsMuscleblind-like 1 (MBNL1) protein sequestrationAlternative splicing defects in MBNL1-regulated exons (e.g., MBNL1, NUMA1, ADD3)Corneal endothelial cell density (ECD)Central corneal thickness (CCT)

Beyond the preview

Go deeper on Transcription factor 4 (TCF4) CTG18.1 expanded CUG-repeat RNA (TCF4 CUG-repeat RNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor 4 (TCF4) CTG18.1 expanded CUG-repeat RNA (TCF4 CUG-repeat RNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call